Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) saw a large increase in short interest in the month of September. As of September 30th, there was short interest totaling 130,722 shares, an increase of 146.8% from the September 15th total of 52,967 shares. Currently, 5.8% of the company’s shares are sold short. Based on an average daily trading volume, of 3,343,756 shares, the short-interest ratio is currently 0.0 days.
Lakewood-Amedex Biotherapeutics Price Performance
Shares of LABT stock opened at $0.63 on Thursday. Lakewood-Amedex Biotherapeutics has a twelve month low of $0.62 and a twelve month high of $98.20. The stock has a fifty day moving average price of $1.83.
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current year.
Analyst Ratings Changes
View Our Latest Stock Analysis on LABT
Lakewood-Amedex Biotherapeutics Company Profile
Lakewood-Amedex Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing anti-infective therapies for bacterial infections. The company’s research is centered on novel antimicrobial compounds intended to address infections caused by drug-resistant bacteria and other pathogens.
Its leading product candidate is Nu-3, a bisphosphocin-based anti-infective therapy being developed for potential use against bacterial infections, including those associated with resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA).
See Also
- Five stocks we like better than Lakewood-Amedex Biotherapeutics
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
